ArticleClinical and experimental nephrology2026
Imeglimin pretreatment improves survival and attenuates sepsis-associated acute kidney injury following Escherichia coli challenge in diabetic mice.
Article in Clinical and experimental nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundSepsis is a serious condition that induces systemic inflammation and multiple organ injuries, including sepsis-associated acute kidney injury (SA-AKI). Diabetes is a risk factor for SA-AKI that can worsen sepsis outcomes. We investigated whether the novel oral antihyperglycemic drug and AMP-kinase (AMPK) activator imeglimin could ameliorate SA-AKI and the survival in diabetic mice by improving the mitochondrial function.
methodsMale C57BLKS/J Iar -+Lepr
resultsThe Ime group showed ameliorated survival rate and kidney injury after E. coli challenge compared to the Veh group in db/db and STZ mice. The Ime group showed a significantly higher p-AMPK/AMPK ratio than Veh. The mitochondrial membrane potential of tubular cells and the kidney ATP concentration improved in the Ime group of both diabetes types, although the recovery of fatty acid oxidation and changes in serum lactate and ketone levels differed between db/db and STZ mice. The level of serum IL-6 was also lower in the Ime group than the Veh group.
conclusionImeglimin could prevent SA-AKI and increase the survival rate after E. coli challenge. The preservation of mitochondrial function via AMPK enhancement by imeglimin presumably resulted in early resolution of the metabolic deterioration due to sepsis.
Indexed as
Identifiers
42837067What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.